Avutometinib Potassium And Defactinib Hydrochloride has 6 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Anakinra, Cyp3a Inducers, Mao Inhibitors. Patients taking Avutometinib Potassium And Defactinib Hydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 4
- Moderate
- 1
Major (4)
- Avutometinib Potassium And Defactinib Hydrochloride + Anakinra— Concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. Avoid concomi…
- Avutometinib Potassium And Defactinib Hydrochloride + Cyp3a Inducers— Concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. Avoid concomi…
- Avutometinib Potassium And Defactinib Hydrochloride + Mao Inhibitors— Concomitant use increases defactinib exposure, which may increase the risk of adverse reactions. Avoid concomitant use.
- Avutometinib Potassium And Defactinib Hydrochloride + Warfarin— Cases of bleeding and increased INR occurred in clinical trials. Avoid concomitant use; use an alternative anticoagulant…
Moderate (1)
- Avutometinib Potassium And Defactinib Hydrochloride + Short-Acting Antacids— If use cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the antacid to minimize exposure reduction…